Show Notes
The world is awash with news that a drug designed to treat type 2 diabetes has also been approved to help achieve weight loss. Glucagon-like peptide 1 — or GLP 1 — is considered by some as a wonder drug and a new weapon in the public health battle against obesity. But what are the wider implications for the investment world? In this episode of Magellan In The Know, Portfolio Manager Nikki Thomas is joined by three Magellan Investment Analysts: Emma Henderson; Wilson Nghe and Tracey Wahlberg. Together they discuss the investment landscape surrounding GLP 1, looking at the pitfalls and potential financial benefits for sectors from healthcare, food retailing and restaurants to fashion, exploring which parts of the consumption landscape could be winners or losers.
More from MAGELLAN - In The Know
What did the latest reporting season reveal about the state of the Australian share market, and could the ASX’s potentially biggest IPO in decades, Firmus Technologies, reshape the picture?
Asset-backed credit is a well-established part of Australia’s lending market, but it operates quite differently from corporate and real estate private credit that has attracted much of the recent attention.
Cellnex owns and operates around 112,000 telecom towers across ten European markets, generating recurring, contracted revenue from mobile operators who have few practical alternatives once a site is built.
Geopolitical events are no longer just creating short-term market volatility, they’re reshaping the global investment landscape in more lasting ways.
How are data and AI reshaping the future of active investing?